Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium

dc.contributor.authorGabriel A. de Erausquin
dc.contributor.authorHeather M. Snyder
dc.contributor.authorTraolach Brugha
dc.contributor.authorSudha Seshadri
dc.contributor.authorMaría C. Carrillo
dc.contributor.authorRajesh Sagar
dc.contributor.authorYueqin Huang
dc.contributor.authorCharles R. Newton
dc.contributor.authorMaria Carmela Tartaglia
dc.contributor.authorCharlotte E. Teunissen
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:14:16Z
dc.date.available2026-03-22T14:14:16Z
dc.date.issued2022
dc.descriptionCitaciones: 26
dc.description.abstractThe following review describes what is known so far in terms of molecular and epidemiological links among COVID-19, the brain, neurological symptoms, and AD and related dementias (ADRD)The primary objective of this large-scale collaboration is to clarify the pathogenesis of ADRD and to advance our understanding of the impact of a neurotropic virus on the long-term risk of cognitive decline and other CNS sequelae. No available evidence supports the notion that cognitive impairment after SARS-CoV-2 infection is a form of dementia (ADRD or otherwise). The longitudinal methodologies espoused by the consortium are intended to provide data to answer this question as clearly as possible controlling for possible confounders. Our specific hypothesis is that SARS-CoV-2 triggers ADRD-like pathology following the extended olfactory cortical network (EOCN) in older individuals with specific genetic susceptibility.The proposed harmonization strategies and flexible study designs offer the possibility to include large samples of under-represented racial and ethnic groups, creating a rich set of harmonized cohorts for future studies of the pathophysiology, determinants, long-term consequences, and trends in cognitive aging, ADRD, and vascular disease.We provide a framework for current and future studies to be carried out within the Consortium. and offers a "green paper" to the research community with a very broad, global base of support, on tools suitable for low- and middle-income countries aimed to compare and combine future longitudinal data on the topic.The Consortium proposes a combination of design and statistical methods as a means of approaching causal inference of the COVID-19 neuropsychiatric sequelae. We expect that deep phenotyping of neuropsychiatric sequelae may provide a series of candidate syndromes with phenomenological and biological characterization that can be further explored. By generating high-quality harmonized data across sites we aim to capture both descriptive and, where possible, causal associations.
dc.identifier.doi10.1002/trc2.12348
dc.identifier.urihttps://doi.org/10.1002/trc2.12348
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/45340
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofAlzheimer s & Dementia Translational Research & Clinical Interventions
dc.sourceInstitute for Neurodegenerative Disorders
dc.subjectMedicine
dc.subjectIntensive care medicine
dc.subjectDisease
dc.subjectAsymptomatic
dc.subjectCerebral amyloid angiopathy
dc.subjectDementia
dc.subjectEpidemiology
dc.subjectStroke (engine)
dc.subjectPsychiatry
dc.titleChronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium
dc.typearticle

Files